Effects of glutamate and aspartate on prostate cancer and breast cancer: a Mendelian randomization study

BMC Genomics

Table 3 MR analysis using different methods for genetic associations between aspartate and breast cancer^a

MR method	Association					Heterogeneity
MR method	Estimate	SE²	95% CI (Down)	95% CI (Up)	P-value	Q	P-value
Simple median	0.030	0.020	-0.009	0.068	0.134
Weighted median	0.031	0.016	-0.001	0.063	0.060
Penalized weighted median	0.031	0.016	-0.001	0.063	0.060
IVW	0.032	0.015	0.004	0.061	0.028	0.4410	0.8021
Penalized IVW	0.032	0.015	0.004	0.061	0.028
Robust IVW	0.032	0.007	0.018	0.046	0.000
Penalized robust IVW	0.032	0.007	0.018	0.046	0.000
MR-Egger	0.015	0.070	-0.122	0.152	0.827
MR-Egger intercept	0.021	0.086	-0.148	0.191	0.805
Penalized MR-Egger	0.015	0.070	-0.122	0.152	0.827
Penalized MR-Egger intercept	0.021	0.086	-0.148	0.191	0.805
Robust MR-Egger	0.015	0.022	-0.029	0.059	0.496
Robust MR-Egger intercept	0.021	0.033	-0.044	0.087	0.521
Penalized robust MR-Egger	0.015	0.022	-0.029	0.059	0.496
Penalized robust MR-Egger intercept	0.021	0.033	-0.044	0.087	0.521
Robust adjusted profile score	0.032				0.036

^aSingle nucleotide polymorphisms with genome-wide significance (P < 5 × 10^–8) were used as genetic predictors.
^bSE Standard Error

ISSN: 1471-2164